Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancercellsmallglioblastomaradiation
  Phrases that lowered it: first doseasthmathe trialparticipantdexamethasone
• Sponsor's past termination rate: 27.0% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 26.3% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 33 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor's past trials: 152 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 6069 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 20436 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma NCT04201873 · started 2020 · scored riskier than 23% of active trials completed
• Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma NCT03665545 · started 2018 · scored riskier than 99% of active trials completed
• Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma NCT03190213 · started 2017 · scored riskier than 94% of active trials terminated
• A Study of Pembrolizumab in Patients With Neuroendocrine Tumors NCT02939651 · started 2016 · scored riskier than 84% of active trials completed
• Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence NCT04013672 · started 2020 · scored riskier than 80% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.